Vaccitech Newsroom
News & updates
ProBioGen and Vaccitech Sign License Agreement for ProBioGen’s Technology Platform
AGE1.CR® Duck Cell Line - Safe and Well tolerated for Large-Scale Production Berlin, Germany, and Oxford, United Kingdom, May 15th, 2019: ProBioGen AG, a premier German service & technology provider for complex biologics and Vaccitech, Ltd., a spin-out company...
Vaccitech Awarded BARDA contract valued at $8.6M to conduct Phase II trial for Influenza Vaccine
Contract includes funding to conduct one of the largest influenza A challenge studies Vaccitech announced today that it has been awarded a contract valued at $8.6 million from the Biomedical Advanced Research and Development Authority (BARDA), a component of...
Vaccitech receives £6M investment from GeneMatrix and Korea Investment Partners
Vaccitech will progress existing vaccine programs and the collaboration will combine Vaccitech’s know-how with GeneMatrix’s clinical network. Oxford, UK and Seoul, South Korea Vaccitech, a clinical stage developer of a universal flu vaccine and other vaccine-related...
Update: INVICTUS Study
Vaccitech has taken the decision not to proceed with season 2 of the current FLU007 (Invictus) study due to the changes recommended by the UK Government which directed the NHS to use FLUAD (adjuvanted TIV) vaccine in the 65 year old and over population in the 2018/19...
Vaccitech licenses MERS rights to Oxford University
CEPI Awards Contract Worth Up To USD$19 million to Oxford University and Janssen Vaccines to Develop MERS, Lassa, and Nipah Vaccines
New UK-China biotech collaboration to develop shingles vaccine
Vaccitech will combine Oxford University vaccine know-how with the manufacturing expertise of China’s CanSino Biologics in collaboration focused on herpes zoster. Vaccitech Limited, a UK-based company developing products to treat and prevent multiple infectious...
VANCE: First in Human Phase I Study of a Novel ChAdOx1-MVA 5T4 Vaccine
View/Download ASCO 2018 Poster
Phase 1 Data on the Vaccitech Prostate Cancer Vaccine Presented at ASCO 2018
Vaccitech Limited, a UK company developing products to treat and prevent multiple infectious diseases and cancer, today announced the presentation of Phase 1 prostate cancer vaccine data at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. In...
Universal Flu Vaccine Data Presented at NFID 2018
Data on safety and immunogenicity of Vaccitech’s flu vaccine have been presented at the 2018 Annual Conference on Vaccinology Research, run by the National Foundation for Infectious Diseases. The presentation was entitled: A Clinical Study to Determine the Safety and...
Flu vaccine Study Recruits First Participants
The world’s first NHS trial for a universal flu vaccine has recruited its first round of participants, with over 862 people signing up to take part since the trial launched in October 2017. This marks the end of the first phase of the trial, which will open again for...